Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
4.04 +0.02 (+0.37%) 13:37 ET [NASDAQ]
4.03 x 127 4.04 x 99
Realtime by (Cboe BZX)
4.03 x 127 4.04 x 99
Realtime 4.12 +0.10 (+2.49%) 09:29 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.01
Day High
4.17
Open 4.08
Previous Close 4.02 4.02
Volume 1,222,428 1,222,428
Avg Vol 3,414,777 3,414,777
Stochastic %K 16.41% 16.41%
Weighted Alpha +112.68 +112.68
5-Day Change -0.09 (-2.04%) -0.09 (-2.04%)
52-Week Range 1.69 - 6.07 1.69 - 6.07
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 618,839
  • Shares Outstanding, K 153,940
  • Annual Sales, $ 203,070 K
  • Annual Income, $ -54,840 K
  • EBIT $ -23 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.37
  • Price/Sales 3.12
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 121.88% ( -17.74%)
  • Historical Volatility 73.29%
  • IV Percentile 76%
  • IV Rank 59.95%
  • IV High 192.96% on 04/30/24
  • IV Low 15.49% on 05/14/24
  • Put/Call Vol Ratio 0.62
  • Today's Volume 55
  • Volume Avg (30-Day) 531
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 9,975
  • Open Int (30-Day) 11,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.08
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +7.10%
on 04/10/25
Period Open: 5.81
6.07 -32.87%
on 03/26/25
-1.74 (-29.86%)
since 03/21/25
3-Month
3.24 +25.77%
on 01/23/25
Period Open: 3.29
6.07 -32.87%
on 03/26/25
+0.78 (+23.86%)
since 01/22/25
52-Week
1.69 +141.12%
on 04/26/24
Period Open: 1.78
6.07 -32.87%
on 03/26/25
+2.29 (+128.93%)
since 04/22/24

Most Recent Stories

More News
Xeris Biopharma - Possibly the best Pharma Stock

Summary Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28. The company offers innovative therapies like Gvoke, Keveyis, and Recorlev,...

XERS : 4.01 (-0.25%)
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

XPH : 38.76 (+1.92%)
XERS : 4.01 (-0.25%)
VTI : 256.92 (+1.71%)
IWM : 185.78 (+1.66%)
Xeris Biopharma: Q4 Earnings Snapshot

Xeris Biopharma: Q4 Earnings Snapshot

XERS : 4.01 (-0.25%)
Xeris Biopharma: Q3 Earnings Snapshot

Xeris Biopharma: Q3 Earnings Snapshot

XERS : 4.01 (-0.25%)
Xeris Biopharma: Q2 Earnings Snapshot

Xeris Biopharma: Q2 Earnings Snapshot

XERS : 4.01 (-0.25%)
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 4.01 (-0.25%)
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSolâ„¢ Formulations

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 4.01 (-0.25%)
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJectâ„¢

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 4.01 (-0.25%)
Xeris Biopharma Appoints Ricki Fairley to Board of Directors

Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 4.01 (-0.25%)
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 4.01 (-0.25%)

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 4.36
2nd Resistance Point 4.27
1st Resistance Point 4.14
Last Price 4.01
1st Support Level 3.92
2nd Support Level 3.83
3rd Support Level 3.70

See More

52-Week High 6.07
Fibonacci 61.8% 4.40
Last Price 4.01
Fibonacci 50% 3.88
Fibonacci 38.2% 3.36
52-Week Low 1.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro